BiotechTube

Lorigerlimab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum-resistant Ovarian Cancer

Conditions

Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer

Trial Timeline

May 1, 2025 → Aug 1, 2027

NCT ID
NCT06730347

About Lorigerlimab

Lorigerlimab is a phase 2 stage product being developed by MacroGenics for Platinum-resistant Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06730347. Target conditions include Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT06730347Phase 2Recruiting
NCT05475171Phase 2Recruiting
NCT03761017Phase 1Completed

Competing Products

16 competing products in Platinum-resistant Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
28
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
E7050 + CetuximabEisaiPhase 1/2
41
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
52
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
41
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
52
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
77
CRS-207 + Epacadostat + PembrolizumabIncytePhase 1/2
38
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
74
Bevacizumab + Irinotecan SucrosofateIpsenPhase 2
49
Gemcitabine + N-803 + M-CENKImmunityBioPhase 2
49
Drug Product De-TIL-0255Nurix TherapeuticsPhase 1
28
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154Shattuck LabsPhase 1
25
CTIM-76Context TherapeuticsPhase 1
25
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3
69
PHI-101 administrationiBioPhase 1
25

Other Products from MacroGenics

Margetuximab + Trastuzumab + Physician's choice of chemotherapy.Phase 3
69
enoblituzumab + MGA012 + MGD013Phase 2/3
57
lorigerlimab + docetaxel + PrednisonePhase 2
44
EnoblituzumabPhase 2
44
Enoblituzumab + Retifanlimab + TebotelimabPhase 2
44